Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | ADK | P55263 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28229366 | 0.98 | PI4KA (0.43) | PI4KAPI4K2BPI4K2API4KBCASP1 | |
| SCHEMBL28791179 | 0.98 | PI4KA (0.43) | PI4KAPI4K2BPI4K2API4KBCASP1 | |
| SCHEMBL28049164 | 0.94 | CASP1 (0.41) | PI4KAPI4K2BPI4K2API4KBCASP1 | |
| SCHEMBL28935141 | 0.89 | CASP1 (0.52) | PI4KAPI4K2BPI4K2API4KBCASP1 | |
| SCHEMBL10872550 | 0.86 | HRH4 (0.39) | PI4KAPI4K2BPI4K2API4KBCASP1 | |
| SCHEMBL4591162 | 0.86 | KCNH2 (0.43) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL2793062 | 0.84 | KCNH2 (0.47) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Ammonia Solution, Strong SCHEMBL29135408 | 0.82 | KCNH2 (0.45) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL7203347 | 0.79 | PI4KA (0.36) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL1542351 | 0.78 | KCNH2 (0.42) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210363154-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2021-11-25 | — | — | US | disclosed |
| CN-106687114-B | Pyrimidine compounds and methods of use thereof | 尤马治疗公司 | 2021-08-31 | — | — | CN | disclosed |
| US-10961254-B2 | Pyrimidine compounds and methods using the same | YUMA THERAPEUTICS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10336768-B2 | Pyrimidine compounds and methods using the same | YUMA THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| CN-108848668-A | Modulators of CFTR and methods of use thereof | 加利福尼亚大学董事会 | 2018-11-20 | — | — | CN | disclosed |
| CN-106687114-A | Pyrimidine compounds and methods using the same | 尤马治疗公司 | 2017-05-17 | — | — | CN | disclosed |
| US-20170107228-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | disclosed |
| EP-3154547-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | Yuma Therapeutics, Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015192119-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | YUMA THERAPEUTICS, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
| US-20060252857-A1 | Aminoaryl-1-3-5-triazines and their use as uv absorbers | SCHAEFER THOMAS | 2006-11-09 | — | — | US | disclosed |
| CN-1795182-A | Aminoaryl-1, 3, 5-triazines and their use as UV absorbers | CIBA SC HOLDING AG (CH) | 2006-06-28 | — | — | CN | disclosed |
| EP-1641768-A2 | AMINOARYL-1-3-5 TRIAZINES AND THEIR USE AS UV ABSORBERS | Ciba SC Holding AG (CH) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004106311-A2 | AMINOARYL-1-3-5 TRIAZINES AND THEIR USE AS UV ABSORBERS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2004-12-09 | — | — | WO | disclosed |
| US-5795905-A | 3-AMINO-5-PHENYL-1,2,4-TRIAZOLES | NEUROCRINE BIOSCIENCES, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0846108-A1 | AMINO-SUBSTITUTED THIADIAZOLES, PYRIMIDINES, TRIAZINES OR TRIAZOLES USEFUL AS CTF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 1998-06-10 | — | — | EP | disclosed |
| WO-1996039400-A1 | AMINO-SUBSTITUTED THIADIAZOLES, PYRIMIDINES, TRIAZINES OR TRIAZOLES USEFUL AS CTF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107228-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | HSP90AB2P, HSPH1, HSF1 | PI4KA 3634/4885PI4K2B 3507/4885PI4K2A 3181/4885 |
| US-20060252857-A1 | Aminoaryl-1-3-5-triazines and their use as uv absorbers | IK, CRY2, CRY1 | PI4KA 3474/4885PI4K2B 3675/4885PI4K2A 3401/4885 |
| US-20210363154-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | HSP90AB2P, HSF1, HSPH1 | PI4KA 2336/4885PI4K2B 2110/4885PI4K2A 1685/4885 |
| US-10336768-B2 | Pyrimidine compounds and methods using the same | HSP90AB2P, HSPH1, HSF1 | PI4KA 3634/4885PI4K2B 3507/4885PI4K2A 3181/4885 |
| US-10961254-B2 | Pyrimidine compounds and methods using the same | HSP90AB2P, HSPH1, HSF1 | PI4KA 3634/4885PI4K2B 3507/4885PI4K2A 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.